Abstract
Abstract Background Diabetes mellitus is considered the ninth major cause of death, biomarkers have been investigated in DM research field to understand the pathophysiology of DM, help in diagnosis and find new therapeutics. This study evaluated the role of Galectin 1, LncRNA MEG3, miR22 in T2DM. Aim of the work we aimed to evaluate the role of galectin 1 expression in type 2 DM and to explore the epigenetic regulatory effect of miRNA22 and LncRNA, MEG3 on gelatin 1 expression in type 2 DM Materials and methods The study included two groups: Fifteen type 2 diabetes mellitus patients and fifteen normal healthy individuals. Blood samples were collected from every participant and serum was separated. Expressions of Gal-1, LncRNA MEG3, miR22 were assessed in each serum sample by quantitative real time polymerase chain reaction (qRT-PCR). Results The study revealed higher levels of gal-1, miR22 and lower levels of MEG3 in serum samples of T2DM Patients compared to normal healthy individuals with statistical significance difference (p < 0.05). Conclusion Gal-1, MEG3, miR22 may play a role in the pathophysiology of T2DM. Studies with larger sample sizes are required to further confirm their role in early detection and diagnosis of T2DM.
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
